Cargando…
The efficacy and safety of IBI314 on delta and omicron variant of SARS-CoV-2: First-in-human evidence
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9183246/ https://www.ncbi.nlm.nih.gov/pubmed/35691517 http://dx.doi.org/10.1016/j.jinf.2022.06.004 |
| _version_ | 1784724239263203328 |
|---|---|
| author | Sang, Ling Cheng, Bo Yu, Yuheng Xi, Yin Wang, Yun Fan, Bingdong Li, Jijie Dai, Jingtao Gan, Guifen Tong, Shijun Sun, Bin Qi, Xiaojing Liang, Wenhua He, Jianxing Zhong, Nanshan |
| author_facet | Sang, Ling Cheng, Bo Yu, Yuheng Xi, Yin Wang, Yun Fan, Bingdong Li, Jijie Dai, Jingtao Gan, Guifen Tong, Shijun Sun, Bin Qi, Xiaojing Liang, Wenhua He, Jianxing Zhong, Nanshan |
| author_sort | Sang, Ling |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9183246 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | The British Infection Association. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91832462022-06-10 The efficacy and safety of IBI314 on delta and omicron variant of SARS-CoV-2: First-in-human evidence Sang, Ling Cheng, Bo Yu, Yuheng Xi, Yin Wang, Yun Fan, Bingdong Li, Jijie Dai, Jingtao Gan, Guifen Tong, Shijun Sun, Bin Qi, Xiaojing Liang, Wenhua He, Jianxing Zhong, Nanshan J Infect Letter to the Editor The British Infection Association. Published by Elsevier Ltd. 2022-09 2022-06-09 /pmc/articles/PMC9183246/ /pubmed/35691517 http://dx.doi.org/10.1016/j.jinf.2022.06.004 Text en © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Sang, Ling Cheng, Bo Yu, Yuheng Xi, Yin Wang, Yun Fan, Bingdong Li, Jijie Dai, Jingtao Gan, Guifen Tong, Shijun Sun, Bin Qi, Xiaojing Liang, Wenhua He, Jianxing Zhong, Nanshan The efficacy and safety of IBI314 on delta and omicron variant of SARS-CoV-2: First-in-human evidence |
| title | The efficacy and safety of IBI314 on delta and omicron variant of SARS-CoV-2: First-in-human evidence |
| title_full | The efficacy and safety of IBI314 on delta and omicron variant of SARS-CoV-2: First-in-human evidence |
| title_fullStr | The efficacy and safety of IBI314 on delta and omicron variant of SARS-CoV-2: First-in-human evidence |
| title_full_unstemmed | The efficacy and safety of IBI314 on delta and omicron variant of SARS-CoV-2: First-in-human evidence |
| title_short | The efficacy and safety of IBI314 on delta and omicron variant of SARS-CoV-2: First-in-human evidence |
| title_sort | efficacy and safety of ibi314 on delta and omicron variant of sars-cov-2: first-in-human evidence |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9183246/ https://www.ncbi.nlm.nih.gov/pubmed/35691517 http://dx.doi.org/10.1016/j.jinf.2022.06.004 |
| work_keys_str_mv | AT sangling theefficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT chengbo theefficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT yuyuheng theefficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT xiyin theefficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT wangyun theefficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT fanbingdong theefficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT lijijie theefficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT daijingtao theefficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT ganguifen theefficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT tongshijun theefficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT sunbin theefficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT qixiaojing theefficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT liangwenhua theefficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT hejianxing theefficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT zhongnanshan theefficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT sangling efficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT chengbo efficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT yuyuheng efficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT xiyin efficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT wangyun efficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT fanbingdong efficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT lijijie efficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT daijingtao efficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT ganguifen efficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT tongshijun efficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT sunbin efficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT qixiaojing efficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT liangwenhua efficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT hejianxing efficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence AT zhongnanshan efficacyandsafetyofibi314ondeltaandomicronvariantofsarscov2firstinhumanevidence |